RemeGen Co. Ltd. Class A
688331
Peringkat dalam Saham
#2419
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces,... RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People's Republic of China.
Harga Saham
$14.71
Kapitalisasi Pasar
$8.24B
Perubahan (1 hari)
1.52%
Perubahan (1 tahun)
7.91%
Negara
CN
Perdagangan RemeGen Co. Ltd. Class A (688331)
Kategori
Healthcare
Pendapatan untuk RemeGen Co. Ltd. Class A (688331)
Pendapatan pada Jun 2026 TTM: $1.16B
Menurut laporan keuangan terbaru dari RemeGen Co. Ltd. Class A, pendapatan saat ini (TTM) adalah $1.16B. Pada tahun 2023, perusahaan menghasilkan pendapatan sebesar $152.99M peningkatan dibandingkan pendapatan pada tahun 2022 yang sebesar $111.93M. Pendapatan adalah jumlah total yang dihasilkan dari penjualan barang atau jasa. Tidak seperti laba, tidak ada pengeluaran yang dikurangkan.
Riwayat pendapatan RemeGen Co. Ltd. Class A dari 2018 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Mengubah |
|---|---|---|
| 2026 (TTM) | $1.16B | 393.27% |
| 2024 | $235.22M | 53.75% |
| 2023 | $152.99M | 36.68% |
| 2022 | $111.93M | -50.04% |
| 2021 | $224.03M | -301,419.47% |
| 2020 | $-74.35K | -119.31% |
| 2019 | $385.06K | -76.60% |
| 2018 | $1.65M | 0.00% |
Pendapatan untuk perusahaan serupa atau pesaing
| Perusahaan | Pendapatan | Perbedaan Pendapatan | Negara |
|---|---|---|---|
| $12.62B | 988.08% |
US
|
|
| $2.23B | 92.03% |
US
|
|
| $15.74B | 1,256.99% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 418.97% |
NL
|
